Our data and the Recursion OS enable us to train intelligent machine learning models for AI drug discovery and development, which help us rapidly identify new targets and design highly optimized …

Recursion's TechBio approach: The future of AI drug discovery In traditional drug discovery, 90% of drugs fail in clinical trials, after more than a decade in development and ~$2 billion in costs. We’re …

Explore Recursion's dynamic drug discovery pipeline. Witness the innovations and breakthroughs in our journey. Dive deeper with us today!

Dec 31, 2025 · SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported …

Get acquainted with the brilliant minds behind Recursion. Dive into our team's passion, expertise, and vision. Read more about our team today!

Sep 1, 2017 · Stay updated with the latest press releases and news from Recursion. Dive into our achievements, announcements, and more. Explore now!

The Investor Relations website contains information about Recursion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

Rare disease and oncology clinical trials At Recursion, we are redefining the drug discovery and development process to bring life-changing treatments to patients faster. Recursion clinical trials are …

Central to our mission is the Recursion Operating System (OS), a platform powered by one of the world’s largest proprietary biological and chemical datasets. Instead of looking narrowly at a handful …

May 28, 2025 · At Recursion, we’ve been building our own proprietary biological datasets for over a decade to help fill in those missing pieces – and we share a subset of those fit-for-purpose datasets …